Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 71 209-249

[2] Ferlay J(2018)Esophageal squamous cell carcinoma and prognosis in Taiwan Cancer Med. 7 4193-4201

[3] Siegel RL(2019)Comparison of clinicopathological features and prognosis between adenocarcinoma of esophagogastric junction and adenocarcinoma of gastric antrum Zhonghua Wei Chang Wai Ke Za Zhi. 22 149-155

[4] Laversanne M(2017)Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: a network meta-analysis Ann Surg. 265 481-491

[5] Soerjomataram I(2018)Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial J Clin Oncol. 36 2796-2803

[6] Jemal A(2009)Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma Dis Esophagus. 22 477-481

[7] Cheng YF(2019)Detecting pathological complete response in esophageal cancer after neoadjuvant therapy based on imaging techniques: a diagnostic systematic review and meta-analysis J Thorac Oncol. 14 1156-1171

[8] Chen HS(2019)Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology J Natl Compr Canc Netw. 17 855-883

[9] Wu SC(2021)The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma J Gastrointest Oncol. 12 1-10

[10] Chen HC(2019)Neoadjuvant chemotherapy increases PD-L1 expression and CD8(+) tumor-infiltrating lymphocytes in esophageal squamous cell carcinoma Anticancer Res. 39 4539-4548

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 71 209-249

[2] Ferlay J(2018)Esophageal squamous cell carcinoma and prognosis in Taiwan Cancer Med. 7 4193-4201

[3] Siegel RL(2019)Comparison of clinicopathological features and prognosis between adenocarcinoma of esophagogastric junction and adenocarcinoma of gastric antrum Zhonghua Wei Chang Wai Ke Za Zhi. 22 149-155

[4] Laversanne M(2017)Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: a network meta-analysis Ann Surg. 265 481-491

[5] Soerjomataram I(2018)Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial J Clin Oncol. 36 2796-2803

[6] Jemal A(2009)Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma Dis Esophagus. 22 477-481

[7] Cheng YF(2019)Detecting pathological complete response in esophageal cancer after neoadjuvant therapy based on imaging techniques: a diagnostic systematic review and meta-analysis J Thorac Oncol. 14 1156-1171

[8] Chen HS(2019)Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology J Natl Compr Canc Netw. 17 855-883

[9] Wu SC(2021)The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma J Gastrointest Oncol. 12 1-10

[10] Chen HC(2019)Neoadjuvant chemotherapy increases PD-L1 expression and CD8(+) tumor-infiltrating lymphocytes in esophageal squamous cell carcinoma Anticancer Res. 39 4539-4548